Announcements Trials

Browse Landscape

Phase

Status

Withdrawn 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 6 Gastrointestinal 4 Genitourinary 3 Breast 3 Sarcoma 2 Other solid neoplasm 1 Lymphoid 1 CNS 1

Conditions

Interventions

Rituximab 55 Cyclophosphamide 45 Vincristine 23 fludarabine phosphate 21 Cytarabine 20 fludarabine 19 Etoposide 19 Prednisone 18 Bendamustine Hydrochloride 18 ibrutinib 17 Methotrexate 17 Doxorubicin 17 Lenalidomide 15 Radiotherapy 14 Peripheral Blood Stem Cell Transplantation 13 Filgrastim 12 venetoclax 11 Melphalan 11 Dexamethasone 11 Whole-Body Irradiation 8 Tacrolimus 8 Busulfan 8 Brentuximab Vedotin 8 Biopsy 8 pembrolizumab 7 duvelisib 7 Nivolumab 7 Mycophenolic Acid 7 Gemcitabine 7 Cyclosporine 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × niraparib × Lymphoid × Clear all

NCT01244009 2016-11-07

A Study of MK-4827 for the Treatment of Mantle Cell Lymphoma (MK-4827-002)

Tesaro, Inc.

Phase 2 Withdrawn

Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡